151. Myoinositol
- Author
-
Keerthana, Rajasekaran, Neena, Malhotra, Reeta, Mahey, Rajesh, Khadgawat, and Mani, Kalaivani
- Subjects
Gonadotropin-Releasing Hormone ,Ovarian Hyperstimulation Syndrome ,Ovulation Induction ,Pregnancy Rate ,Pregnancy ,Humans ,Female ,Fertilization in Vitro ,Inositol ,Metformin ,Polycystic Ovary Syndrome - Abstract
To study the effects of myoinositol (Myo) in comparison to metformin (Met), in reducing the risk of OHSS and improving ART outcome in PCOS women undergoing IVF.Double-blinded randomized controlled trial (CTRI/2018/05/014196).ART Clinic, AIIMS, New Delhi patients: 102 infertile PCOS women undergoing IVF cycles were enrolled after evaluating for eligibility and allotted as 50 in group 1 (Myo) and 52 in group 2 (Met) after randomization.Recruited patients received Myo 2 g twice daily (group 1) and Met 850 mg twice daily (group 2). Pre- and post-treatment clinical (menstrual pattern, BMI), hormonal profile (LH, FSH, testosterone, prolactin [PRL], and AMH), biochemical parameters (HOMA IR, fasting glucose, and insulin), ovarian with antral follicle count (AFC) and side effect profile were assessed. After 3 months of therapy, patients were recruited for IVF cycle by antagonist protocol was involving controlled ovarian stimulation, cycle monitoring, oocyte recovery, insemination of oocytes and follow up with fertilization, cleavage, transfer of good grade cleavage embryos, or blastocysts pregnancy outcomes and OHSS incidence and medications was continued until the day of OPU.Primary outcome was OHSS and clinical pregnancy rate including spontaneous, IVF, and cumulative pregnancy rate including FET. Secondary outcome was ART outcomes and the change in biochemistry and hormonal profile between groups and inter group after medications at 12 weeks.Incidence of OHSS (Myo 5 (10.0) (Myo is equally beneficial as Met in reducing the risk of OHSS and has better ART outcome in PCOS women undergoing antagonist cycles.
- Published
- 2021